title: PTEN augments SPARC suppression of proliferation and inhibits SPARC-induced migration by suppressing SHC-RAF-ERK and AKT signaling.
abstract: SPARC (secreted protein acidic and rich in cysteine) is expressed in all grades of astrocytoma, including glioblastoma (GBM). SPARC suppresses glioma growth but promotes migration and invasion by mediating integrin and growth factor receptor-regulated kinases and their downstream effectors. PTEN (phosphatase and tensin homolog deleted on chromosome 10), which is commonly lost in primary GBMs, negatively regulates proliferation and migration by inhibiting some of the same SPARC-mediated signaling pathways. This study determined whether PTEN reconstitution in PTEN-mutant, SPARC-expressing U87MG cells could further suppress proliferation and tumor growth but inhibit migration and invasion in SPARC-expressing cells in vitro and in vivo, and thereby prolong survival in animals with xenograft tumors. In vitro, PTEN reduced proliferation and migration in both SPARC-expressing and control cells, with a greater suppression in SPARC-expressing cells. PTEN reconstitution suppressed AKT activation in SPARC-expressing and control cells but suppressed the SHC-RAF-ERK signaling pathway only in SPARC-expressing cells. Importantly, coexpression of SPARC and PTEN resulted in the smallest, least proliferative tumors with reduced invasive capacity and longer animal survival. Furthermore, direct inhibition of the AKT and SHC-RAF-ERK signaling pathways suppressed the proliferation and migration of SPARC-expressing cells in vitro. These findings demonstrate that PTEN reconstitution or inhibition of signaling pathways that are activated by the loss of PTEN provide potential therapeutic strategies to inhibit SPARC-induced invasion while enhancing the negative effect of SPARC on tumor growth.
authors.affiliation: Barbara Jane Levy Laboratory of Molecular Neuro-Oncology, Hermelin Brain Tumor Center, Department of Neurosurgery, Henry Ford Hospital, Detroit, Michigan 48202, USA.
authors.forename: Stacey L
authors.initials: SL
authors.lastname: Thomas
authors.forename: Ridwan
authors.initials: R
authors.lastname: Alam
authors.forename: Nancy
authors.initials: N
authors.lastname: Lemke
authors.forename: Lonni R
authors.initials: LR
authors.lastname: Schultz
authors.forename: Jorge A
authors.initials: JA
authors.lastname: Gutiérrez
authors.forename: Sandra A
authors.initials: SA
authors.lastname: Rempel
mesh_terms: D000818:Animals; D015153:Blotting, Western; D001932:Brain Neoplasms / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D002465:Cell Movement / Q000502:physiology; D049109:Cell Proliferation; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism; D005909:Glioblastoma / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D007150:Immunohistochemistry; D051379:Mice; D015676:Osteonectin / Q000378:metabolism*; D051059:PTEN Phosphohydrolase / Q000378:metabolism*; D051057:Proto-Oncogene Proteins c-akt / Q000378:metabolism; D055765:Shc Signaling Adaptor Proteins / Q000378:metabolism; D015398:Signal Transduction / Q000502:physiology*; D023041:Xenograft Model Antitumor Assays; D048490:raf Kinases / Q000378:metabolism
chemical_list: D015676:Osteonectin; D055765:Shc Signaling Adaptor Proteins; D051057:Proto-Oncogene Proteins c-akt; D048490:raf Kinases; D048049:Extracellular Signal-Regulated MAP Kinases; D051059:PTEN Phosphohydrolase; C494929:PTEN protein, human
references.citation: Proc Natl Acad Sci U S A. 1992 Feb 15;89(4):1281-5
references.pmid: 1311092
references.citation: J Biol Chem. 1998 Nov 6;273(45):29635-40
references.pmid: 9792673
references.citation: Mol Biol Cell. 2003 Dec;14(12):4813-25
references.pmid: 12960424
references.citation: Int J Oncol. 2006 Dec;29(6):1349-57
references.pmid: 17088972
references.citation: Cancer Res. 2008 Mar 15;68(6):1862-71
references.pmid: 18339867
references.citation: Int J Cancer. 2008 Jun 15;122(12):2735-43
references.pmid: 18350569
references.citation: J Neurooncol. 2002 Dec;60(3):213-26
references.pmid: 12510773
references.citation: J Biol Chem. 2008 Aug 15;283(33):22826-37
references.pmid: 18503049
references.citation: Neuro Oncol. 2002 Jul;4(3):196-211
references.pmid: 12084351
references.citation: Nat Genet. 1997 Apr;15(4):356-62
references.pmid: 9090379
references.citation: Cancer Res. 1999 Nov 1;59(21):5479-82
references.pmid: 10554022
references.citation: J Biol Chem. 2005 Oct 28;280(43):36483-93
references.pmid: 16115889
references.citation: Neuro Oncol. 2003 Oct;5(4):244-54
references.pmid: 14565160
references.citation: Proc Natl Acad Sci U S A. 2001 Apr 10;98(8):4622-7
references.pmid: 11274365
references.citation: Int J Cancer. 2005 Dec 20;117(6):905-12
references.pmid: 15986432
references.citation: Proc Natl Acad Sci U S A. 1998 Dec 22;95(26):15406-11
references.pmid: 9860981
references.citation: Cancer Res. 1999 Jan 15;59(2):442-9
references.pmid: 9927060
references.citation: Glia. 2008 Aug 1;56(10):1061-75
references.pmid: 18442089
references.citation: Cancer Res. 2008 Mar 15;68(6):1723-31
references.pmid: 18339852
references.citation: J Cell Biol. 1993 Jun;121(6):1433-44
references.pmid: 8509459
references.citation: Science. 1997 Mar 28;275(5308):1943-7
references.pmid: 9072974
references.citation: Science. 2008 Sep 26;321(5897):1807-12
references.pmid: 18772396
references.citation: J Cell Biol. 1998 Nov 30;143(5):1375-83
references.pmid: 9832564
references.citation: Int J Dev Neurosci. 1999 Aug-Oct;17(5-6):463-72
references.pmid: 10571408
references.citation: Cancer Res. 2002 Nov 1;62(21):6318-22
references.pmid: 12414663
references.citation: Proc Natl Acad Sci U S A. 1997 Nov 11;94(23):12479-84
references.pmid: 9356475
references.citation: Neurosci Lett. 2007 May 29;419(2):172-7
references.pmid: 17490812
references.citation: Cancer Res. 2002 Nov 1;62(21):6270-7
references.pmid: 12414657
references.citation: Oncogene. 2001 Oct 11;20(46):6669-78
references.pmid: 11709701
references.citation: J Biol Chem. 2003 May 2;278(18):15951-7
references.pmid: 12590137
references.citation: Cancer Res. 1998 Jun 1;58(11):2331-4
references.pmid: 9622068
references.citation: Oncologist. 2006 Feb;11(2):152-64
references.pmid: 16476836
references.citation: Oncogene. 2008 Sep 18;27(41):5416-30
references.pmid: 18794877
references.citation: J Cell Biol. 1999 Jul 26;146(2):389-403
references.pmid: 10427092
references.citation: Oncogene. 2007 Jun 14;26(28):4084-94
references.pmid: 17213807
references.citation: Science. 1998 Jun 5;280(5369):1614-7
references.pmid: 9616126
references.citation: Nature. 2008 Oct 23;455(7216):1061-8
references.pmid: 18772890
references.citation: Int J Oncol. 2006 Jul;29(1):73-81
references.pmid: 16773187
references.citation: Cancer Res. 2003 May 1;63(9):2300-5
references.pmid: 12727853
references.citation: J Neuropathol Exp Neurol. 1998 Dec;57(12):1112-21
references.pmid: 9862633
references.citation: Stem Cells. 2008 Oct;26(10):2735-45
references.pmid: 18583538
references.citation: J Cell Biol. 2001 Dec 24;155(7):1129-35
references.pmid: 11756467
references.citation: J Neurooncol. 2001 Jun;53(2):149-60
references.pmid: 11716067